AstraZeneca begins European exit—will invest $50 billion in the U.S. amid tariff threats

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.

A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030.

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals,”...